Subtype
Renal Cell Carcinoma
CI-CAN-00006578RCCExplore in graph →
375 active trials17 approved drugs60 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006578RCCExplore in graph →
Clinical trials
1,621 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (276)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001703 | Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jul 25, 2014 | clinicaltrials |
| NCT01793636 | A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer(ZEBRA) | terminated | Phase 2 | 49 | Queen Mary University of LondonOTHER | 1 | Jun 24, 2014 |
| clinicaltrials |
| NCT00303862 | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00684996 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT00523640 | A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 30 | University of ChicagoOTHER | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00110344 | Research Study for Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 1 | BayerINDUSTRY | 1 | Oct 11, 2013 | clinicaltrials |
| NCT00203866 | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 40 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00557830 | Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 12 | Accelerated Community Oncology Research NetworkOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00009919 | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00100685 | Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | terminated | Phase 2 | 48 | AbbottINDUSTRY | 1 | Apr 27, 2012 | clinicaltrials |
| NCT00485563 | A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 12 | EndocyteINDUSTRY | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00561912 | Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 26, 2011 | clinicaltrials |
| NCT00277316 | Study of XL999 in Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 11 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 19, 2010 | clinicaltrials |
| NCT00491738 | A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | terminated | Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Apr 10, 2009 | clinicaltrials |
| NCT00417677 | A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 124 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 28, 2007 | clinicaltrials |
| NCT00131651 | ATN-161 in Advanced Renal Cell Cancer | terminated | Phase 2 | 36 | AttenuonINDUSTRY | 1 | Dec 6, 2007 | clinicaltrials |
| NCT00151645 | Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. | terminated | Phase 2 | 36 | Rennes University HospitalOTHER | 1 | Jan 2, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Jul 25, 2014source: clinicaltrials